American Century Companies Inc. lifted its holdings in shares of OptiNose Inc (NASDAQ:OPTN) by 46.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 157,790 shares of the company’s stock after purchasing an additional 50,058 shares during the period. American Century Companies Inc. owned 0.42% of OptiNose worth $4,415,000 as of its most recent filing with the SEC.
Several other large investors have also modified their holdings of the company. Thompson Davis & CO. Inc. bought a new position in OptiNose during the second quarter worth $105,000. Northern Trust Corp raised its stake in OptiNose by 5.7% during the first quarter. Northern Trust Corp now owns 79,072 shares of the company’s stock worth $1,583,000 after buying an additional 4,246 shares during the last quarter. TIAA CREF Investment Management LLC bought a new position in OptiNose during the fourth quarter worth $173,000. Massachusetts Financial Services Co. MA raised its stake in OptiNose by 1.4% during the second quarter. Massachusetts Financial Services Co. MA now owns 703,962 shares of the company’s stock worth $19,697,000 after buying an additional 9,763 shares during the last quarter. Finally, Millennium Management LLC bought a new position in OptiNose during the fourth quarter worth $190,000. Institutional investors own 46.84% of the company’s stock.
In related news, CEO Peter K. Miller purchased 10,752 shares of the firm’s stock in a transaction on Wednesday, August 15th. The stock was purchased at an average cost of $14.32 per share, with a total value of $153,968.64. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Thomas Edward Gibbs purchased 2,000 shares of the firm’s stock in a transaction on Wednesday, August 15th. The stock was bought at an average cost of $12.69 per share, with a total value of $25,380.00. The disclosure for this purchase can be found here. Insiders own 67.80% of the company’s stock.
Shares of NASDAQ OPTN opened at $14.25 on Friday. OptiNose Inc has a twelve month low of $12.51 and a twelve month high of $30.00. The company has a quick ratio of 10.82, a current ratio of 11.03 and a debt-to-equity ratio of 0.44. The firm has a market cap of $612.95 million and a P/E ratio of -2.66.
OptiNose (NASDAQ:OPTN) last posted its quarterly earnings results on Tuesday, August 14th. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.13. The company had revenue of $1.27 million during the quarter, compared to the consensus estimate of $1.01 million. research analysts predict that OptiNose Inc will post -2.94 EPS for the current fiscal year.
A number of equities analysts recently weighed in on OPTN shares. Piper Jaffray Companies set a $30.00 target price on shares of OptiNose and gave the stock a “buy” rating in a research note on Tuesday, August 14th. Cantor Fitzgerald set a $30.00 target price on shares of OptiNose and gave the stock a “buy” rating in a research note on Tuesday, August 14th. Zacks Investment Research raised shares of OptiNose from a “hold” rating to a “buy” rating and set a $30.00 target price for the company in a research note on Wednesday, July 18th. Finally, BMO Capital Markets lowered their target price on shares of OptiNose from $30.00 to $28.00 and set an “outperform” rating for the company in a research note on Wednesday, August 15th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $29.67.
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Recommended Story: Diversification For Individual Investors
Want to see what other hedge funds are holding OPTN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OptiNose Inc (NASDAQ:OPTN).
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.